This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read KALA BIO’s 8K filing here.
KALA BIO Company Profile
KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.
Further Reading
- Five stocks we like better than KALA BIO
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- 3 Reasons Micron Stock Is Deeply Undervalued Right Now
- Stock Average Calculator
- Inflation Persists, But So Do Stock Opportunities: Rally On
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Energy Transfer Fuels the Cloud: A Natural Gas Power Play
